|
1
|
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial.
|
J Clin Psychiatry
|
2008
|
0.95
|
|
2
|
More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2011
|
0.81
|
|
3
|
Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study.
|
Int J Neuropsychopharmacol
|
2009
|
0.78
|
|
4
|
Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase.
|
Hum Psychopharmacol
|
2011
|
0.77
|
|
5
|
More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial.
|
Hum Psychopharmacol
|
2010
|
0.76
|
|
6
|
Altered expression of myeloperoxidase precursor, myeloid cell nuclear differentiation antigen, Fms-related tyrosine kinase 3 ligand, and antigen CD11A genes in leukocytes of clozapine-treated schizophrenic patients.
|
J Clin Psychopharmacol
|
2006
|
0.75
|